Katsaros D - Search Results

1

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.

Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall M, Steer CB, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M, Ray-Coquard I, Ferrero A, Favier L, Reed NS, Curé H, Pujade-Lauraine E. Vergote IB, et al. Among authors: katsaros d. J Clin Oncol. 2014 Feb 1;32(4):320-6. doi: 10.1200/JCO.2013.50.5669. Epub 2013 Dec 23. J Clin Oncol. 2014. PMID: 24366937 Clinical Trial.

2

Phase II trial with 5-fluorouracil and high-dose folinic acid, using new sequential dosing schedule, in pretreated advanced breast cancer patients.

Zola P, Bergamino T, Katsaros D, Ferrero A, Ciancio A, Bellora G, Sismondi P. Zola P, et al. Among authors: katsaros d. Eur J Gynaecol Oncol. 1992;13(6):527-32. Eur J Gynaecol Oncol. 1992. PMID: 1473534 Clinical Trial.

3

The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis.

Luo LY, Katsaros D, Scorilas A, Fracchioli S, Bellino R, van Gramberen M, de Bruijn H, Henrik A, Stenman UH, Massobrio M, van der Zee AG, Vergote I, Diamandis EP. Luo LY, et al. Among authors: katsaros d. Cancer Res. 2003 Feb 15;63(4):807-11. Cancer Res. 2003. PMID: 12591730

4

Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma.

Diamandis EP, Scorilas A, Fracchioli S, Van Gramberen M, De Bruijn H, Henrik A, Soosaipillai A, Grass L, Yousef GM, Stenman UH, Massobrio M, Van Der Zee AG, Vergote I, Katsaros D. Diamandis EP, et al. Among authors: katsaros d. J Clin Oncol. 2003 Mar 15;21(6):1035-43. doi: 10.1200/JCO.2003.02.022. J Clin Oncol. 2003. PMID: 12637468

5

Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer.

Katsaros D, Cho W, Singal R, Fracchioli S, Rigault De La Longrais IA, Arisio R, Massobrio M, Smith M, Zheng W, Glass J, Yu H. Katsaros D, et al. Gynecol Oncol. 2004 Sep;94(3):685-92. doi: 10.1016/j.ygyno.2004.06.018. Gynecol Oncol. 2004. PMID: 15350359

6

Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma.

Katsaros D, Oletti MV, Rigault de la Longrais IA, Ferrero A, Celano A, Fracchioli S, Donadio M, Passera R, Cattel L, Bumma C. Katsaros D, et al. Ann Oncol. 2005 Feb;16(2):300-6. doi: 10.1093/annonc/mdi055. Ann Oncol. 2005. PMID: 15668288 Free article. Clinical Trial.

7

Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study.

Buda A, Fossati R, Colombo N, Fei F, Floriani I, Gueli Alletti D, Katsaros D, Landoni F, Lissoni A, Malzoni C, Sartori E, Scollo P, Torri V, Zola P, Mangioni C. Buda A, et al. Among authors: katsaros d. J Clin Oncol. 2005 Jun 20;23(18):4137-45. doi: 10.1200/JCO.2005.04.172. J Clin Oncol. 2005. PMID: 15961761 Clinical Trial.

8

Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study.

Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Selvaggi L, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Marforio G, Ballardini M, Lombardi AV, Sorio R, Tumolo S, Costa B, Magni G, Perrone F, Favalli G; SOCRATES and MITO investigators. Pignata S, et al. Among authors: katsaros d. Oncology. 2006;71(5-6):320-6. doi: 10.1159/000108592. Epub 2007 Sep 18. Oncology. 2006. PMID: 17878745

9

ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.

Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D. Smith S, et al. Among authors: katsaros d. J Clin Oncol. 2007 Nov 20;25(33):5172-9. doi: 10.1200/JCO.2007.11.8547. J Clin Oncol. 2007. PMID: 18024864

10

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.

Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, Scambia G. Ferrandina G, et al. Among authors: katsaros d. J Clin Oncol. 2008 Feb 20;26(6):890-6. doi: 10.1200/JCO.2007.13.6606. J Clin Oncol. 2008. PMID: 18281662 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

247 results

Search Page

Filters